Ph I Safety and Efficacy of ODSH in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
2021年11月3日 更新者:Chimerix
A Pilot Study to Evaluate the Safety and Preliminary Evidence of a Therapeutic Effect of ODSH (2-0, 3-0, Desulfated Heparin) in Patients Receiving Induction or Consolidation Therapy for Acute Myeloid Leukemia
This is an open-label pilot study evaluating the safety and preliminary evidence of a therapeutic effect of ODSH (2-0, 3-0 desulfated heparin) in conjunction with standard induction and consolidation therapy for acute myeloid leukemia.
研究概览
研究类型
介入性
注册 (实际的)
10
阶段
- 第一阶段早期
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Utah
-
Salt Lake City、Utah、美国、84112
- Huntsman Cancer Institute
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 70年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Newly diagnosed, previously untreated acute myeloid leukemia. Acute promyelocytic leukemia is excluded.
- No prior chemotherapy for acute myeloid leukemia; however, prior hydroxyurea to control white blood cell count is allowed.
- No prior chemotherapy or lenalinomide for treatment of myelodysplastic syndrome.
- Age: 18-70.
- ECOG Performance status 0-2
- Cardiac ejection fraction ≥ 50% (echocardiography or MUGA [multigated acquisition])
- Adequate hepatic and renal function (AST [aminotransferase], ALT [alanine aminotransferase], bilirubin and creatinine < 2.5 x upper normal limit).
- Able to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines.
Exclusion Criteria:
- Patients with acute promyelocytic leukemia
- Patients with acute megakaryoblastic leukemia
- Patients with CNS (central nervous system) leukemia
- Presence of significant active infection or uncontrolled bleeding
- Any coexisting major illness or organ failure which contraindicates the dose-intensive chemotherapy regimen prescribed by this protocol
- Pre-existing liver disease that might impair ODSH clearance
- History of other active malignant disease within 5 years, other than cured basal cell carcinoma of the skin, cured in situ carcinoma of the cervix, or localized prostate cancer that has received definitive therapy. Such prostate cancer patients who are receiving hormonal therapy are eligible
- Use of recreational drugs or history of drug addiction, within the prior 6 months
- Known history of positive hepatitis B surface antigens or hepatitis C antibodies
- Known history of positive test for HIV (Human immunodeficiency virus) antibodies
- Psychiatric or neurologic conditions that could impair ability to give proper informed consent
- Presence of symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia
- Presence of uncontrolled thrombotic or hemorrhagic disorder
- A medical condition that requires the need to be on chronic anticoagulation
- Presence of any other serious uncontrolled medical disorder
- Treatment with any other investigational agent, or participation in another clinical trial within 28 days prior to study entry
- Pregnant or breast-feeding patients
- Patient with childbearing potential not using adequate contraception
- Hemorrhage risk that requires maintenance of platelet counts at 50,000/uL or higher.
- Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:ODSH
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
Safety by incidence of serious events
大体时间:12 months
|
12 months
|
|
Efficacy by time to platelet recovery
大体时间:12 months
|
12 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
赞助
调查人员
- 首席研究员:Paul J Shami, M.D.、Huntsman Cancer Institute
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2013年8月1日
初级完成 (实际的)
2015年4月1日
研究完成 (实际的)
2015年4月1日
研究注册日期
首次提交
2013年4月26日
首先提交符合 QC 标准的
2013年4月26日
首次发布 (估计)
2013年4月30日
研究记录更新
最后更新发布 (实际的)
2021年11月10日
上次提交的符合 QC 标准的更新
2021年11月3日
最后验证
2015年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.